Libtayo was the sixth PD-L/PD-L1 inhibitor to reach the market, starting out as a therapy for another skin cancer called cutaneous squamous cell carcinoma (CSCC), and the rarity of that disease ...

Sanofi’s cancer immunotherapy Libtayo (cemiplimab) has a third US indication after the FDA approved it for certain untreated lung cancer patients. The approval in first-line lung cancer ...

Revenues also missed the Zacks Consensus Estimate of $3.27 billion. Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results.

The acquisition of 23andMe aims to enhance personalized health solutions. Significant progress in oncology with Libtayo and bispecific antibodies was presented. The Factor XI program targets safer ...

TARRYTOWN, N.Y., May 01, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: REGN) today announced new and updated data from its oncology and hematology portfolio will be shared at the ...

Dupixent US Net Sales: $2.6 billion, up 19% year-over-year. Libtayo Global Net Sales: $285 million, up 8% year-over-year on a constant currency basis. Free Cash Flow: $816 million for Q1 2025.

Highlights from the ASCO presentations will include results from the Phase 3 C-POST trial, which explores the adjuvant use of PD-1 inhibitor Libtayo in high-risk cutaneous squamous cell carcinoma ...

Oncology Programs The Company submitted an sBLA to the FDA and a regulatory application in the EU for Libtayo (cemiplimab) in adjuvant CSCC based upon data from a Phase 3 trial which demonstrated ...